Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

Kevin R. Kelly, MD, PhD
Published: Friday, Feb 10, 2017



Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.
 


Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x